Tarik Skubal, Colt Keith and an out-of-rhythm road trip: 6 Tigers takeaways
The Detroit Tigers are coming home with a 2-4 record. There are 156 games remaining on their schedule. There is much left to ...
Rhythm jumps after late-stage trial win; BofA upgrades (update)
Rhythm Pharma (RYTM) stock rises as lead asset setmelanotide succeeds in a Phase 3 trial for a rare obesity type, causing an ...
Rhythm Pharmaceuticals price target raised to $77 from $72 at Morgan Stanley
Morgan Stanley analyst Michael Ulz raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $77 from $72 and keeps an Overweight ...
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial
Rhythm Pharmaceuticals said on Monday that its experimental drug to treat a rare obesity disorder met the main goal in a late-stage trial.
Rhythm Pharma's drug for rare obesity meets late-stage trial goal
Rhythm Pharmaceuticals said on Monday its drug Imcivree notably reduced weight in patients with a rare obesity disorder caused by damage to the brain, meeting the main goal of a late-stage trial.
Rhythm Pharmaceuticals upgraded to Buy from Neutral at BofA
BofA analyst Tazeen Ahmad upgraded Rhythm Pharmaceuticals (RYTM) to Buy from Neutral.Don't Miss Our End of Quarter Offers: Discover the latest ...